APEXPerformancePeptideLab R3ta
Product Specifications
Compound: R3ta
Quantity: 10mg, 20mg or 30mg per vial
Purity: ≥99% (HPLC Verified)
Form: Lyophilized powder
Quality: Research Grade
Testing: Independently verified for identity and purity
APEX Retatrutide is a next-generation multi-receptor peptide agonist developed for advanced metabolic research. It is uniquely designed to interact with GLP-1, GIP, and glucagon receptors, making it a powerful compound for studies focused on energy regulation, fat metabolism, and metabolic efficiency.
Retatrutide represents a significant evolution beyond single-pathway incretin peptides, offering researchers a tool to explore broader metabolic signaling and adaptive energy output
This product is for research use only.
Not for human or veterinary use.
Not intended to diagnose, treat, cure, or prevent any disease.
Coskun, T. et al. (2022). Triple-hormone receptor agonist retatrutide for obesity.New England Journal of Medicine, 387(21), 2057–2066.DOI: 10.1056/NEJMoa2206038
Jastreboff, A.M. et al. (2023). Multi-agonist peptides and metabolic outcomes.Nature Reviews Endocrinology, 19, 123–136.
Campbell, J.E. & Drucker, D.J. (2013). Pharmacology of incretin hormones.Cell Metabolism, 17(6), 819–837.
Müller, T.D. et al. (2018). Glucagon receptor signaling in energy balance.Molecular Metabolism, 10, 1–14
